Free Cash Flow for Gilead Sciences (GILD)
Free Cash Flow for Gilead Sciences (GILD): headline value $9.46B · YoY -8.2%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
GILD
Currently viewingFree Cash FlowSwitch metric
Latest period
$9.46B
YoY change
-8.2%
5Y CAGR
+4.7%
Peak year (2015)
$20.50B
Latest annual
$9.46B
Free Cash Flow history chart for Gilead Sciences (GILD) from 1990 to 2025
Free Cash Flow history table for Gilead Sciences (GILD) from 1990 to 2025
| Fiscal year | Period ended | Reported | Free Cash Flow | YoY |
|---|---|---|---|---|
| 2025 | $9.46B | -8.2% | ||
| 2024 | $10.30B | +38.9% | ||
| 2023 | $7.42B | -11.1% | ||
| 2022 | $8.34B | -22.8% | ||
| 2021 | $10.80B | +43.7% | ||
| 2020 | $7.52B | -9.6% | ||
| 2019 | $8.32B | +11.3% | ||
| 2018 | $7.48B | -33.9% | ||
| 2017 | $11.31B | -30.6% | ||
| 2016 | $16.30B | -20.5% | ||
| 2015 | $20.50B | +67.2% | ||
| 2014 | $12.26B | +320.6% | ||
| 2013 | $2.92B | +4.2% | ||
| 2012 | $2.80B | -20.2% | ||
| 2011 | $3.51B | +26.5% | ||
| 2010 | $2.77B | -2.7% | ||
| 2009 | $2.85B | +40.5% | ||
| 2008 | $2.03B | +20.3% | ||
| 2007 | $1.69B | +51.6% | ||
| 2006 | $1.11B | +69.2% | ||
| 2005 | $657.69M | +44.0% | ||
| 2004 | $456.60M | +133.0% | ||
| 2003 | $196.00M | +245.0% | ||
| 2002 | $56.81M | -137.1% | ||
| 2001 | -$153.31M | +184.8% | ||
| 2000 | -$53.82M | -28.3% | ||
| 1999 | -$75.10M | +20.5% | ||
| 1998 | -$62.30M | -8.8% | ||
| 1997 | -$68.30M | +238.1% | ||
| 1996 | -$20.20M | -14.4% | ||
| 1995 | -$23.60M | -24.6% | ||
| 1994 | -$31.30M | — | ||
| 1992 | -$13.30M | +216.7% | ||
| 1991 | -$4.20M | +55.6% | ||
| 1990 | -$2.70M | — |
Free Cash Flow values are taken from Gilead Sciences's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
In 2025, Gilead Sciences (GILD) free cash flow totalled $9.46B – declined 8.2% year-over-year.
Gilead Sciences free cash flow has recorded the values shown across consecutive periods, with a +4.7% compound annual growth rate over 2020–2025 (5 years).
Between 2015 and 2025, Gilead Sciences free cash flow plunged 53.9%, falling from $20.50B to $9.46B.
The dataset's maximum free cash flow sits at $20.50B (2015); the minimum reading of -$153.31M dates to 2001.
Among 8 Healthcare peers, Gilead Sciences (GILD) ranks 7th; the peer median for free cash flow is $14.22B.
Gilead Sciences Free Cash Flow by Year
Gilead Sciences Free Cash Flow 2025: $9.46B
Gilead Sciences free cash flow in 2025 was $9.46B, declined 8.2% below 2024.
Gilead Sciences Free Cash Flow 2024: $10.30B
Gilead Sciences free cash flow in 2024 was $10.30B, surged 38.9% from 2023.
Gilead Sciences Free Cash Flow 2023: $7.42B
Gilead Sciences free cash flow in 2023 was $7.42B, declined 11.1% below 2022.
Gilead Sciences Free Cash Flow 2022: $8.34B
Gilead Sciences free cash flow in 2022 was $8.34B, declined 22.8% below 2021.
Gilead Sciences Free Cash Flow 2021: $10.80B
Gilead Sciences free cash flow in 2021 was $10.80B.
See more financial history for Gilead Sciences (GILD).
Sector peers — Free Cash Flow
Companies in the same sector as Gilead Sciences, ranked by their latest free cash flow.
| Company | Free Cash Flow | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $28.99B | Healthcare |
| Johnson & Johnson (JNJ) | $19.70B | Healthcare |
| AbbVie Inc. (ABBV) | $17.82B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $16.07B | Healthcare |
| Merck & Co., Inc. (MRK) | $12.36B | Healthcare |
| AstraZeneca PLC (AZN) | $11.77B | Healthcare |
| Eli Lilly and Company (LLY) | $8.97B | Healthcare |
| Amgen Inc. (AMGN) | $8.10B | Healthcare |
Frequently asked questions
What is Gilead Sciences's free cash flow?
Latest reported free cash flow for Gilead Sciences (GILD) is $9.46B (period ending December 31, 2025).
How has Gilead Sciences free cash flow changed year-over-year?
Gilead Sciences (GILD) free cash flow changed -8.2% year-over-year on the latest annual filing.
What is the long-term growth rate of Gilead Sciences free cash flow?
Gilead Sciences (GILD) free cash flow compound annual growth rate is +4.7% over the most recent 5 years available.
When did Gilead Sciences free cash flow hit its highest annual value?
Gilead Sciences free cash flow reached its highest annual value of $20.50B in 2015.
What was Gilead Sciences free cash flow in 2024?
Gilead Sciences (GILD) free cash flow in 2024 was $10.30B.
What was Gilead Sciences free cash flow in 2025?
Gilead Sciences (GILD) free cash flow in 2025 was $9.46B.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
GILD Overview
Company profile, financial tools, and key metrics
GILD Revenue Counter
Earns $933.60 every second. See per minute, hour, and day.
GILD Earnings Counter
Earns $269.85 per second net profit. See per minute, hour, and day.
GILD Economic Scale
Exceeds Albania's GDP. Compare with world economies.
GILD What If Invested
What if you had invested $1,000? See historical returns from any date.
GILD How It Makes Money
Discover visual breakdown of $29.44B in revenue — where it comes from and where it goes.
GILD Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
GILD Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
GILD Daily Price Character
Explosive · 48.7% historical win rate (green days). Streaks & record days.
GILD Buybacks
1.26% TTM buyback yield. Shareholder yield & SBC comparison.
GILD Stock Split History
5 splits on record. Dates, ratios, and cumulative multiple.
GILD Dividend Profile
Yield: 2.48%. Safety: 8/8. See full history.
GILD Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
GILD Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.